0512-67998889(Suzhou)
18051093220(Shenzhen)
[Good News] RocRock Biotechnology Crowned with Both Technology and Innovation Awards for Small and Medium-sized Enterprises
Recently, with the release of the "Provincial Department of Science and Technology's Public Notice on the List of Science and Technology SMEs in Jiangsu Province for the First Batch of 2024" and the "Suzhou City's Public Notice on the List of Innovative SMEs for 2024," RocRock Biotechnology has received good news on both fronts, successfully being selected as a science and technology SME and an innovative SME for 2024.
[The Power Behind the Honor: Innovation as the Driving Force]
This honor is not only a high recognition of RocRock Biotechnology's many years of effort and achievements in the field of CAR-M treatment for solid tumors, but also an affirmation of RocRock's spirit of innovation and technological strength, which further motivates RocRock to forge ahead on the path of technological innovation in the future.
In the rapidly developing field of biomedicine, strongly supported by the national strategy, RocRock has always adhered to technology leadership and innovation-driven development since its establishment, committed to making affordable anti-cancer drugs for the public. Through independent research and development and technological innovation, RocRock has successfully created four unique technology platforms and obtained 21 national authorized patents. These platforms focus on solving long-standing technical challenges in the industry, especially in the cultivation and transduction of macrophages. Continuously innovating in research and development and stabilizing production processes, RocRock has advanced two cellular drugs to the IIT stage, and the latest biotechnological product, RR-M01 cell injection, has completed clinical administration in five subjects, with its safety and efficacy further verified.
【 Wings of Technology: Empowering the Future 】
RocRock Biotechnology is well aware that technology is the primary productive force leading future development. The company is committed to transforming the most cutting-edge scientific and technological achievements into real productive forces, by continuously optimizing R&D processes and production technologies, introducing high-end talents, and increasing investment in scientific research. Technology empowers cell therapy, and RocRock has pioneered the third-generation CAR-M.
The third-generation CAR-M by RocRock Biotechnology, based on the original CAR, incorporates cytokines necessary for the autologous proliferation and activation of macrophages, enhancing the persistence of CAR-M in the body, altering the tumor microenvironment, and further strengthening the macrophages' ability to engulf, kill tumors, and present antigens. The third-generation CAR-M has achieved full independent research and development and 100% domestic production, which is the result of the entire team's intelligence and hard work. It was recognized as a disruptive technology by the state in 2021 and approved as a national flagship project in 2023, holding significant strategic importance.
This recognition not only signifies RocRock Biotechnology's leading position in the field of biotechnology but also adds strong momentum for the company to further expand its market and enhance its competitiveness.
[Looking Ahead: Continuous Innovation, Creating Brilliance Together]
The recognition as a technology-based small enterprise and an innovative small enterprise has provided RocRock Biotechnology with richer resources and a broader space for development. Looking ahead, RocRock Biotechnology will continue to guide itself with scientific and technological innovation, oriented by market demand, and adhere to its original aspiration to firmly advance the industrialization process of the macrophage pipeline. Deepening industry-academia-research cooperation, accelerating technology transformation and application, and promoting high-quality development in the field of cell therapy. We firmly believe that under the wings of technology, RocRock Biotechnology will fly higher and further, creating greater value for society and writing more brilliant chapters.
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)